FDA Extends ZymoGenetics’ rhThrombin Action Date To Jan. 17
This article was originally published in The Pink Sheet Daily
Executive Summary
ZymoGenetics and commercialization partner Bayer will use the three-month extension to hone plans for “aggressively converting the market,” firm tells “The Pink Sheet” DAILY.